Tylenol Maker Kenvue Faces Mounting Pressure From Lawsuits, Political Statements, and Investor Concerns
Kenvue, the parent company of Tylenol, is battling legal challenges, political scrutiny, and declining investor confidence, leading to a 40% drop in its stock value over the past six months.
The latest pressure comes from U.S. Health Secretary and follows recent comments from Robert F. Kennedy Jr. regarding a potential link between acetaminophen use during pregnancy and autism, despite a lack of definitive proof. Kennedy stated to reporters in Washington, “The causative association between Tylenol given in pregnancy and the perinatal period is not sufficient to say it definitely causes autism. But it’s very suggestive.” This adds to concerns initially raised in September when President Donald Trump publicly advised pregnant women to avoid Tylenol.
Last week, the state of Texas filed a lawsuit against Kenvue and its former parent company, Johnson & Johnson, alleging they failed to adequately warn consumers about potential neurological risks associated with acetaminophen use during pregnancy. The lawsuit is intensifying calls for the Food and Drug Administration to mandate stricter labeling requirements for acetaminophen-based products. Kenvue maintains there is no conclusive evidence linking acetaminophen to autism and cautions that disseminating misleading information could harm women’s health. The company’s second quarter 2025 net sales fell by 4.0%, with organic revenue down 4.2%.
These challenges come as Kenvue navigates broader financial headwinds, including a late allergy season impacting self-care product sales, consumer price sensitivity, and ongoing inflationary pressures. Credit rating agencies Moody’s and S&P have both downgraded Kenvue’s outlook to negative. Activist investor Starboard Value launched a proxy fight earlier this year, and the company’s former CEO, Thibaut Mongon, departed in July. The situation highlights the potential for eroding public trust in established over-the-counter medications, which could have ripple effects across the pharmaceutical industry.
Officials are closely monitoring the situation, and Kenvue is expected to address investor concerns during its upcoming earnings calls.
